Trial start Not phased (device or behavioral study): Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects With Open-Angle Glaucoma source ↗
FDA FDA 510(k) clearance: VIA360 Surgical System — K243503, Feb 14, 2025. Applicant at approval: New World Medical, Inc. source ↗
Trial start —: An Extension Trial for Patients With Open-Angle Glaucoma Who Participated in the DF6-CL-20-01 Protocol. source ↗
Trial start Not phased (device or behavioral study): STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma source ↗
Trial start Not phased (device or behavioral study): A First in Human Clinical Trial to Evaluate the Safety and Effectiveness of the STREAMLINE SURGICAL SYSTEM in Patients With Open-Angle Glaucoma source ↗
Trial start Not phased (device or behavioral study): A FIH Trial of the STREAMLINE™ SURGICAL SYSTEM source ↗
Trial start Not phased (device or behavioral study): A First-In-Human Clinical Trial to Evaluate the Safety, Effectiveness and Surgical Characteristics of CADENCE in Patients With Refractory Glaucoma source ↗
Trial start Not phased (device or behavioral study): A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction source ↗
Upcoming milestones
2027-09 (ESTIMATED) · Not phased · Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects With Open-Angle Glaucoma · NCT05696561
Estimated primary completion per ClinicalTrials.gov. Dates move.
A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction
Not phased (device or behavioral study)
Completed
2016-06
2017-12 (actual)
FDA records (last 2 years)
FDA 510(k) clearance: VIA360 Surgical System — K243503, Feb 14, 2025. Applicant at approval: New World Medical, Inc. source ↗
NIH awards 4
Annual award amounts. Total $983K.
NIH award 5R44EY015587-03 FY2008: $396,769 awarded for that fiscal year; activity R44 (SBIR); PI AHMED, ABDUL M; recipient as written: NEW WORLD MEDICAL, INC., RANCHO CUCAMONGA, CA. DEVELOPMENT OF A NOVEL GLAUCOMA IM source ↗
NIH award 2R44EY015587-02 FY2007: $394,694 awarded for that fiscal year; activity R44 (SBIR); PI AHMED, ABDUL M; recipient as written: NEW WORLD MEDICAL, INC., RANCHO CUCAMONGA, CA. DEVELOPMENT OF A NOVEL GLAUCOMA IM source ↗
NIH award 1R43EY015587-01 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI AHMED, ABDUL M; recipient as written: NEW WORLD MEDICAL, INC., RANCHO CUCAMONGA, CA. DEVELOPMENT OF A NOVEL GLAUCOMA IM source ↗
NIH award 1R43NS036477-01 FY1997: $91,709 awarded for that fiscal year; activity R43 (SBIR); PI AHMED, ABDUL M; recipient as written: NEW WORLD MEDICAL, INC., RANCHO CUCAMONGA, CA. SELF-REGULATING NONOBSTRUCTIVE HYDR source ↗
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
